Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Reaching for additions usually signals that the actual goal has drifted to something KLOW does not target (fat loss, GH-axis effects, cognition), in which case the right move is a purpose-built protocol for that goal, not a heavier KLOW
The compound has never received market authorization in Canada or anywhere else, and Metabolic Pharmaceuticals terminated clinical development in 2007 after the Phase IIb obesity trial failed
It is a 29-amino acid polypeptide representing the 129 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH
Researchers examine how this growth hormone fragment affects fat cell function, lipid mobilization, glucose metabolism, and weight regulation in experimental systems focused on obesity, metabolic syndrome, and lipid disorders
US$ 20.81
US$ 26.46
US$ 21.45
US$ 26.33
